Regeneron Pharmaceuticals (NQ:REGN)

735.20 UNCHANGED

Delayed Quote Updated: 4:00 PM EDT, Oct 2, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Regeneron Pharmaceuticals

< Previous 1 2

...

10 11 12 13 14 15 16 17 18

...

66 67 Next >

What's going on in today's session: S&P500 movers ↗

August 20, 2025

Stay updated with the movement of S&P500 stocks in today's session. Discover which S&P500 stocks are making waves on Wednesday.

Via Chartmill

Regeneron Says FDA Will Take More Time to Review Its Two Eylea HD Submissions ↗

August 20, 2025

Via Stocktwits

EYLEA HD® (aflibercept) Injection 8 mg Applications for Expanded U.S. Label and Prefilled Syringe Receive FDA Review Period Extension

August 20, 2025

From Regeneron Pharmaceuticals, Inc.

Via GlobeNewswire

3 of Wall Street’s Favorite Stocks with Open Questions

August 19, 2025

Wall Street has set ambitious price targets for the stocks in this article. While this suggests attractive upside potential, it’s important to remain skeptical because analysts face institutional...

Via StockStory

Immuno-Oncology Stocks Q2 In Review: Incyte (NASDAQ:INCY) Vs Peers

August 17, 2025

As the Q2 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the immuno-oncology industry, including Incyte (NASDAQ:INCY) and its peers.

Via StockStory

Topics Artificial Intelligence

These S&P500 stocks are moving in today's session ↗

August 14, 2025

Curious about the S&P500 stocks that are in motion on Thursday? Join us as we explore the top movers within the S&P500 index during today's session.

Via Chartmill

REGN Q2 Deep Dive: New Indications and Pipeline Progress Offset EYLEA Challenges

August 12, 2025

Biotech company Regeneron (NASDAQ:REGN) reported revenue ahead of Wall Street’s expectations in Q2 CY2025, with sales up 3.6% year on year to $3.68 billion. Its non-GAAP profit of $12.89 per share was...

Via StockStory

Amphastar Pharmaceuticals, QuidelOrtho, Integra LifeSciences, Select Medical, and Regeneron Stocks Trade Up, What You Need To Know

August 12, 2025

A number of stocks jumped in the afternoon session after positive inflation data fueled hopes for an interest rate cut by the Federal Reserve. The latest Consumer Price Index (CPI) report showed...

Via StockStory

Topics Bonds Economy Lawsuit

This Stock Has Tumbled 50% In One Year, Gets A Price Target Cut Today – But Retail Believes $400-450 Is A Good Entry Point ↗

August 11, 2025

Truist, however, kept a ‘Buy’ rating on the shares.

Via Stocktwits

A Look Into Regeneron Pharmaceuticals Inc's Price Over Earnings ↗

August 11, 2025

Via Benzinga

How Do Investors Really Feel About Regeneron Pharmaceuticals? ↗

August 08, 2025

Via Benzinga

Regeneron Announces Investor Conference Presentations

August 07, 2025

From Regeneron Pharmaceuticals, Inc.

Via GlobeNewswire

These Analysts Increase Their Forecasts On Regeneron Pharmaceuticals After Better-Than-Expected Earnings ↗

August 04, 2025

Via Benzinga

Beyond The Numbers: 15 Analysts Discuss Regeneron Pharmaceuticals Stock ↗

August 04, 2025

Via Benzinga

Is Regeneron Pharmaceuticals Gaining or Losing Market Support? ↗

August 04, 2025

Via Benzinga

2 Biotech Stocks That Could Soar 29% and 165% According to Wall Street's Top Analysts ↗

August 03, 2025

These biotech businesses look compelling for very different reasons.

Via The Motley Fool

Regeneron (REGN) Q2 EPS Jumps 53% ↗

August 02, 2025

Via The Motley Fool

Why Regeneron (REGN) Stock Is Trading Up Today

August 01, 2025

Shares of biotech company Regeneron (NASDAQ:REGN) jumped 3.3% in the morning session after the company reported strong second-quarter financial results that significantly surpassed analyst...

Via StockStory

Topics Artificial Intelligence

Stocks Sell Off, Gold Rallies On Tariff Turmoil, Weak Jobs Data: What's Moving Markets Friday? ↗

August 01, 2025

It's a rough start to the new month for Wall Street, as major U.S. stock indices plunged by midday Friday, setting the stage for a negative weekly close.

Via Benzinga

4D Molecular Therapeutics Rallies On Heels Of Diabetes-Related Vision Study ↗

August 01, 2025

4D Molecular's 4D-150 showed sustained vision and anatomical improvements with fewer injections in DME, supported by regulatory alignment.

Via Benzinga

Regeneron's Pipeline Hit By Catalent Delays, But Dupixent Shines ↗

August 01, 2025

Regeneron Q2 revenue rose 4% to $3.68 billion, driven by Dupixent and antibody profits, while FDA delays impacted Eylea HD and odronextamab approvals.

Via Benzinga

Regeneron Pharmaceuticals (NASDAQ:REGN) Beats Q2 2025 Earnings Estimates but Faces Muted Market Reaction ↗

August 01, 2025

Regeneron Q2 2025 earnings beat estimates with $3.68B revenue and $12.89 EPS, but stock dips in pre-market trading. Dupixent sales surge 22% to $4.34B.

Via Chartmill

Topics Earnings

Regeneron’s (NASDAQ:REGN) Q2: Strong Sales

August 01, 2025

Via StockStory

Regeneron Reports Second Quarter 2025 Financial and Operating Results

August 01, 2025

From Regeneron Pharmaceuticals, Inc.

Via GlobeNewswire

Regeneron Pharmaceuticals Likely To Report Lower Q2 Earnings; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call ↗

August 01, 2025

Via Benzinga

Earnings Scheduled For August 1, 2025 ↗

August 01, 2025

Via Benzinga

Trump Turns Up Heat On Big Pharma CEOs To Slash Drug Prices Within 60 Days — But Retail Traders Don't Flinch ↗

July 31, 2025

Via Stocktwits

Topics Government

Exploring Regeneron Pharmaceuticals's Earnings Expectations ↗

July 31, 2025

Via Benzinga

Regeneron (REGN) Q2 Earnings: What To Expect

July 30, 2025

Biotech company Regeneron (NASDAQ:REGN) will be reporting earnings this Friday before market open. Here’s what investors should know.

Via StockStory

Topics Artificial Intelligence Government World Trade

2 Healthcare Stocks That Are Losing to the S&P 500 This Year ↗

July 27, 2025

Wall Street might be underestimating these companies' potential.

Via The Motley Fool

Topics Stocks

< Previous 1 2

...

10 11 12 13 14 15 16 17 18

...

66 67 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.